Junshi Bio (01877): Teriprizumab received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Junshi Biosciences (01877) announced that the European commodity name for Teriprizumab monoclonal antibody is LOQTORZI...

Zhitong FinanceJul 26 09:44 ET

Express News | Shanghai Junshi Biosciences - Receipt of Positive Opinion From Committee for Medicinal Products for Human Use of EMA for Toripalimab

ReutersJul 26 09:44 ET

The Market Doesn't Like What It Sees From Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Yet

Simply Wall StJul 25 01:42 ET

Shanghai Junshi Biosciences' Supplementary NDA Accepted by Chinese Regulator

MT NewswiresJul 18 04:10 ET

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined With Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

GlobeNewswireJul 17 23:38 ET

HKEX News | Junshi Biosciences (01877) rose more than 4% as the new application for Trelagliptin monoclonal antibody was accepted.

Junshi Bio (01877) rose more than 4%. As of press time, it rose 4.11% to HKD 13.16 with a turnover of HKD 4.2279 million.

Zhitong FinanceJul 17 21:57 ET